Whigan D B, Schuster A E
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4500, USA.
J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):357-63. doi: 10.1016/0378-4347(94)00487-p.
This paper describes the determination of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in urine. The method involves sample clean-up by liquid-liquid extraction with ethyl acetate followed by high-performance liquid chromatographic (HPLC) analysis. The sample preparation may be performed either manually or automatically using a Zymark Py-robotic system. The chloro analog of the parent compound, CV-araU, is used as the internal standard. As low as 0.1 microgram of analyte per ml of urine can be measured. This sensitivity is adequate for pharmacokinetic studies but could be improved quite easily if necessary.
本文描述了尿液中1-β-D-阿拉伯呋喃糖基-E-5-(2-溴乙烯基)尿嘧啶的测定方法。该方法包括用乙酸乙酯进行液-液萃取以净化样品，随后进行高效液相色谱（HPLC）分析。样品制备可以手动进行，也可以使用Zymark Py-机器人系统自动进行。母体化合物的氯类似物CV-araU用作内标。每毫升尿液中低至0.1微克的分析物都可以被检测到。这种灵敏度对于药代动力学研究来说是足够的，但如有必要可以很容易地提高。
